Ionis Pharmaceuticals
IONS
382 hedge funds and large institutions have $6.8B invested in Ionis Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 68 funds opening new positions, 123 increasing their positions, 113 reducing their positions, and 49 closing their positions.
152% more call options, than puts
Call options by funds: $88.4M | Put options by funds: $35M
39% more first-time investments, than exits
New positions opened: 68 | Existing positions closed: 49
21% more capital invested
Capital invested by funds: $5.62B → $6.8B (+$1.18B)
4% more funds holding
Funds holding: 367 → 382 (+15)
1.07% more ownership
Funds ownership: 84.86% → 85.94% (+1.1%)
9% more repeat investments, than reductions
Existing positions increased: 123 | Existing positions reduced: 113
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$119M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$94.5M |
| 3 |
BlackRock
New York
|
+$64M |
| 4 |
JP Morgan Chase
New York
|
+$57.1M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$40.5M |
Top Sellers
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$239M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$67M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$41.2M |
| 4 |
Two Sigma Investments
New York
|
-$39.1M |
| 5 |
Renaissance Technologies
New York
|
-$36M |
IONS Hedge Fund Activity: Q4 2020 in Review
382 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q4 2020, worth a combined $6.8B — up 21% from $5.62B a quarter earlier.
Buyers outnumbered sellers: 68 funds opened new IONS positions and 49 closed out — a net gain of 19 holders — while 123 added to existing stakes and 113 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $119M. The largest seller was Baillie Gifford & Co, cutting an estimated $239M.
- 382 institutional investors held Ionis Pharmaceuticals (IONS) as of Q4 2020, up from 367 in Q3 2020.
- Funds reported $6.8B of Ionis Pharmaceuticals stock for Q4 2020, up 21% quarter-over-quarter.
- 68 funds opened new Ionis Pharmaceuticals positions in Q4 2020 and 49 closed out, a net change of +19 holders.
- The largest Ionis Pharmaceuticals buyer in Q4 2020 was T. Rowe Price Associates, an estimated $119M added.
- The largest Ionis Pharmaceuticals seller in Q4 2020 was Baillie Gifford & Co, an estimated $239M sold.
Based on aggregated 13F filings for Q4 2020.